IDYA Stock Analysis: Buy, Sell, or Hold?
IDYA - IDEAYA Biosciences, Inc. Common Stock
$39.67
0.56 (1.43%)
▲
5d:
+9.28%
30d:
+9.49%
90d:
+34.29%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When IDYA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IDYA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IDYA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IDYA is currently trading at $39.67, which is considered extended relative to its 30-day fair value range of $35.44 to $37.70.
Technical Outlook: Technically, IDYA is in a strong uptrend. The price is approaching resistance at $40.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IDYA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.15 (+31.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IDYA is in a strong uptrend. The price is approaching resistance at $40.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IDYA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.15 (+31.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$35.44 -
$37.70
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range (+5.2% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.5% below Wall St target ($52.15)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$35.44 -
$37.70
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$35.66
Resistance Level
$40.56
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.66
Wall Street Target
$52.15
(+31.5%)
Revenue Growth (YoY)
55.4%
Profit Margin
-74.8%
Share & Embed Analysis
Last updated: August 22, 2026 11:03 PM ET
Data refreshes hourly during market hours. Next update: 12:03 AM
Data refreshes hourly during market hours. Next update: 12:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IDYA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jeffrey Stein
BUY
50000 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
